Arcturus Therapeutics Holdings (ARCT) Accumulated Expenses (2018 - 2025)
Arcturus Therapeutics Holdings (ARCT) has disclosed Accumulated Expenses for 8 consecutive years, with $23.9 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Accumulated Expenses rose 79.62% year-over-year to $23.9 million, compared with a TTM value of $23.9 million through Dec 2025, up 79.62%, and an annual FY2025 reading of $23.9 million, up 79.62% over the prior year.
- Accumulated Expenses was $23.9 million for Q4 2025 at Arcturus Therapeutics Holdings, up from $13.3 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $33.6 million in Q2 2022 and bottomed at $3.6 million in Q4 2021.
- Average Accumulated Expenses over 5 years is $14.0 million, with a median of $6.9 million recorded in 2022.
- The sharpest move saw Accumulated Expenses tumbled 82.66% in 2021, then soared 508.51% in 2022.
- Year by year, Accumulated Expenses stood at $3.6 million in 2021, then grew by 12.86% to $4.0 million in 2022, then skyrocketed by 46.56% to $5.9 million in 2023, then skyrocketed by 124.82% to $13.3 million in 2024, then skyrocketed by 79.62% to $23.9 million in 2025.
- Business Quant data shows Accumulated Expenses for ARCT at $23.9 million in Q4 2025, $13.3 million in Q4 2024, and $32.4 million in Q3 2024.